Abbott Closes Acquisition of Alere
By LabMedica International staff writers Posted on 11 Oct 2017 |
Abbott (Lake Bluff, IL; USA) has closed the acquisition of Alere, Inc. (Waltham, MA; USA), following the receipt of all regulatory clearances required for the closing.
Abbott is a global healthcare company with a portfolio of offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, while Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. The transaction makes Abbott the global leader in point of care testing and further strengthens the company's diagnostics presence.
Point of care testing is a USD 7 billion segment of the USD 50 billion in vitro diagnostics market and is growing rapidly as a number of health care systems are increasing their reliance on these technologies to inform patient care decisions with easy-to-use tests that provide speed and accuracy, particularly in the outpatient setting. With the addition of Alere, Abbott has approximately USD 7 billion in diagnostics sales worldwide, including about USD 2.5 billion in point of care testing.
“Creating the world's leading point of care business will help Abbott meet the growing demand for fast, accurate and actionable information,” said Brian Blaser, executive vice president, Diagnostics Products, Abbott. “Combined with Abbott's existing point of care business and its leading hand-held platform, i-STAT, we now have the broadest point of care testing portfolio to help improve care for patients in more parts of the world.”
Abbott is a global healthcare company with a portfolio of offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, while Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. The transaction makes Abbott the global leader in point of care testing and further strengthens the company's diagnostics presence.
Point of care testing is a USD 7 billion segment of the USD 50 billion in vitro diagnostics market and is growing rapidly as a number of health care systems are increasing their reliance on these technologies to inform patient care decisions with easy-to-use tests that provide speed and accuracy, particularly in the outpatient setting. With the addition of Alere, Abbott has approximately USD 7 billion in diagnostics sales worldwide, including about USD 2.5 billion in point of care testing.
“Creating the world's leading point of care business will help Abbott meet the growing demand for fast, accurate and actionable information,” said Brian Blaser, executive vice president, Diagnostics Products, Abbott. “Combined with Abbott's existing point of care business and its leading hand-held platform, i-STAT, we now have the broadest point of care testing portfolio to help improve care for patients in more parts of the world.”
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus